[{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"OBI-902","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Inapplicable"}]

Find FDA Investigational New Drug (IND) Submissions for Oncology in TAIWAN

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. It is being evaluated for advanced solid tumors.

                          Product Name : OBI-902

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          April 30, 2025

                          Lead Product(s) : OBI-902

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.

                          Product Name : OBI-992

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : OBI-992

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Biosion

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of relapsed refractory solid tumors in children & young adults.

                          Product Name : CX-4945

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 08, 2024

                          Lead Product(s) : Silmitasertib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ACE2016 is an allogeneic gamma delta 2 T cell therapy. It's IND application is cleared after preclinical studies for the treatment of EGFR-expressing malignancies in patients with solid tumors.

                          Product Name : ACE2016

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 02, 2024

                          Lead Product(s) : ACE2016

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OBI-992 is a TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor, evaluated for advanced solid tumors including lung and gastric cancers.

                          Product Name : OBI-992

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          March 01, 2024

                          Lead Product(s) : OBI-992

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ACE2016 is an off-the-shelf, gamma delta-2 T cell therapy designed to recognize and engage solid tumors expressing EGFR by ACC technology unlocking multiple receptor signaling causing tumor cell apoptosis.

                          Product Name : ACE2016

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 27, 2023

                          Lead Product(s) : ACE2016

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Pidnarulex synthetically derived small molecule in combination with Talazoparib (PARP inhibitor), potential therapy in patients with metastatic castration-resistant prostate cancer.

                          Product Name : CX-5461

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 22, 2021

                          Lead Product(s) : Pidnarulex,Talazoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Peter MacCallum Cancer Centre

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Acepodia received clearance of its Investigational IND application from U.S FDA to start Phase 1 clinical study of its natural killer cell therapy ACE1702 in patients with HER2-expressing solid tumors.

                          Product Name : ACE1702

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 01, 2020

                          Lead Product(s) : ACE1702

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank